Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants

• Status: Unknown status
• Trial end date: 2015-10-01

Summary

We investigate parameters of hemocoagulation and lipoperoxidation in women using combined oral contraceptives with antiandrogenic activity (containing drospirenone with 20 or 30 mcg ethinylestradiol; or cyproterone acetate); correction of these changes by antioxidants

• Phase: Phase 4

Details

• Lead Sponsor: Tyumen State Medical Academy
• Treatments: Antioxidants; Contraceptive Agents; Contraceptives, Oral; Contraceptives, Oral, Combined; Cyproterone; Cyproterone Acetate; Cyproterone acetate, ethinyl estradiol drug combination; Drospirenone; Drospirenone and ethinyl estradiol combination; Ethinyl Estradiol